Compare Bristol-Myers Squibb Co (BMY) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Okta, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.77 (market cap $129.94B), while Okta, Inc. trades at $148.07 (market cap $26.13B). The key difference: Bristol-Myers Squibb Co is far larger — about 5× Okta, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| BMY | OKTA | |
|---|---|---|
Market Cap | $129.94B | $26.13B |
Sector | Health | Technology |
52-Week High | $65.89 | $154.62 |
52-Week Low | $42.60 | $62.93 |
Enterprise Value | $163.92B | $23.95B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Okta trades at $150.04, down 0.48% today, near its pivot point of $150 with bullish moving averages but overbought RSI signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding expectations. Revenue growth is robust, rising to $2.61B in 2025, while the firm achieved GAAP profitability with net income of $28M, a significant turnaround from prior losses. Recent news highlights Okta's acquisition of Permiso Security to enhance AI-driven identity threat detection, positioning it in the expanding cybersecurity market.
Outlook is positive with analyst consensus at Buy (72.55%) and a $129.71 price target, though current price exceeds this. Opportunities include sustained revenue growth and margin expansion, while risks involve high valuation multiples (P/E 108.93) and competitive pressure from Microsoft. Institutional activity shows mixed signals, with some funds increasing stakes amid the stock's 55.6% YTD gain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
